Legend Biotech reports Q1 EPS (3c), consensus (17c)

Reports Q1 revenue $305.1M, consensus $306.52M. “We believe CARVYKTI’s continued adoption and strong year-over-year growth reinforce our leadership in BCMA CAR-T and the strength of our underlying operating model,” said Ying Huang, Chief Executive Officer of Legend Biotech (LEGN). “As scale continues to build, we are seeing operating leverage translate into improving margins, supporting our path toward sustainable profitability. This continued progress is enabling us to advance our broad pipeline of cell therapy programs and extend the impact of our platform to address unmet needs for patients across multiple indications.”